Fig. 2: MGMT fusions cells show enhanced TMZ resistance via increased MGMT expression.
From: MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas
a Colony-forming assay performed on U251 and U87 cells expressing sgCtrl, BTRC-MGMT, NFYC-MGMT, SAR1A-MGMT, CTBP2-MGMT exposed for 12 days to TMZ (100 μM) or DMSO. b MGMT quantitative-PCRs performed on mRNA from U251 and U87 TMZ-resistant single-cell clones expressing the indicated MGMT fusions. Data are from a representative experiment of n = 3 biological replicate. Centre of the bars represent the mean (technical replicate n = 3) and the error bars are the standard deviations. c Analysis of MGMT promoter methylation, by methylation-specific PCR (MSP), in the TMZ-resistant cell clones expressing the indicated MGMT fusions from U251 (left panel) and U87 (right panel). M and U lanes indicate methylated and unmethylated status of the promoter, respectively. LN18 and U87 cells are shown as control for unmethylated and methylated, respectively. d Western blot analysis of MGMT protein levels in TMZ-resistant cell clones from U251 and U87 expressing the indicated MGMT fusions. Source data are provided as a Source Data file.
